Catis Inc. (140430) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Catis Inc. (140430:KRX), powered by AI.

Current Price
₩828
P/E Ratio
-7.5
Market Cap
15.8B
Sector
Industrials
What is the Catis Inc. stock price forecast?

Catis Inc. is currently trading at ₩828. View real-time AI analysis on Alpha Lenz.

What is Catis Inc. insider trading activity?

View the latest insider trading data for Catis Inc. on Alpha Lenz.

What is Catis Inc.'s P/E ratio?

Catis Inc.'s P/E ratio is -7.5.

Catis Inc.

KRX · 140430
₩828
Ask about Catis Inc.'s future dividend policy...
Alpha Chat Insight

Catis Inc. trades at a P/E of -7.5 (undervalued) with modest ROE of -19.2%. 3Y revenue CAGR of 13.9% highlights clear growth momentum.

Ask for details

Company Overview

Catis Inc., a prominent player in the bio-pharmaceutical industry, specializes in the development and commercialization of innovative therapeutic solutions aimed at addressing unmet medical needs. With a focus on advancing treatment options, Catis Inc. invests heavily in research and development to create cutting-edge drugs and technologies that have the potential to revolutionize patient care. The company's product pipeline includes a variety of treatments targeting chronic diseases, rare disorders, and life-threatening conditions, making significant strides in oncology and neurology. Catis Inc. plays a vital role in the healthcare sector, contributing to critical improvements in medical research and patient outcomes. Its partnerships with major healthcare institutions and research organizations enable it to leverage collaborative efforts and expand its impact across the pharmaceutical landscape. Additionally, Catis Inc. is involved in large-scale production and distribution networks, ensuring that its products are accessible to a global patient base. With its commitment to innovation and excellence, Catis Inc. stands out as a key entity in advancing medical science and providing essential healthcare solutions.

CEO김승수
SectorIndustrials
IndustryBuilding Products & Equipment
0

Company Statistics

FY 2024

Profile

₩15,816,637,332Market Cap
₩31,672,914,120Revenue
19.10MShares Out
0Employees

Margins

25.16%Gross
-12.43%EBITDA
5.03%Operating
-18.43%Pre-Tax
-16.07%Net

Valuation

-7.47P/E
1.15P/B
1.20EV/Sales
-11.21EV/EBITDA
-3.94P/FCF

Growth (CAGR)

13.92%Rev 3Yr
N/ARev 5Yr
-8.27%Op Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-10.66%ROA
-19.15%ROE
-11.22%ROIC

Financial Health

₩7,267,785,290Cash & Cash Equivalents
₩15,916,745,830Net Debt
70.23%Debt/Equity
N/AInterest Cov
Alpha Chat Insight

Catis Inc. trades at a P/E of -7.5 (undervalued) with modest ROE of -19.2%. 3Y revenue CAGR of 13.9% highlights clear growth momentum.

Ask for details

Frequently Asked Questions

Catis Inc. (ticker: 140430) is a company listed on KRX in the Industrials sector (Building Products & Equipment). Market cap is $15.8B.

The current price is ₩828 with a P/E ratio of -7.48x and P/B of 1.15x.

ROE is -19.15% and operating margin is 5.03%. Annual revenue is $31.7B.

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Catis Inc. (Industrials) Stock Forecast & Analysis ₩828 | Alpha Lenz